Quarterly ResultMay 5, 2026, 04:40 PM
Alcon Q1 Sales $2.7B, EPS $0.39; Authorizes $1.5B Share Buyback
AI Summary
Alcon reported first-quarter 2026 sales of $2.7 billion, a 10% increase (6% constant currency) year-over-year, driven by new product launches. Diluted EPS was $0.39, while core diluted EPS rose 16% to $0.85. The company's shareholders approved a dividend of CHF 0.28 per share, and the Board authorized a new $1.5 billion share repurchase program over three years. Alcon also updated its 2026 core diluted EPS growth outlook to +10% to +13%.
Key Highlights
- New $1.5 billion share repurchase authorized over 3 years.
- Q1 2026 sales were $2.7 billion, up 10% (6% cc) from Q1 2025.
- Diluted EPS was $0.39; core diluted EPS was $0.85, up 16% (10% cc).
- Dividend of CHF 0.28 per share approved at AGM, totaling up to $177 million.
- Surgical net sales grew 10% to $1.5 billion (6% cc).
- Vision Care net sales grew 9% to $1.2 billion (6% cc).
- Net cash flows from operating activities increased to $418 million.
- 2026 core diluted EPS growth outlook updated to +10% to +13%.